A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Condition(s):Advanced Solid TumorsLast Updated:June 16, 2022Terminated
Hide Studies Not Open or Pending
Condition(s):Advanced Solid TumorsLast Updated:June 16, 2022Terminated
Condition(s):Advanced Solid TumorsLast Updated:March 14, 2022Unknown status
Condition(s):Advanced Solid TumorLast Updated:April 25, 2023Not yet recruiting
Condition(s):Advanced Solid TumorLast Updated:July 12, 2023Completed
Condition(s):Advanced Solid TumorLast Updated:September 6, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:February 28, 2024Recruiting
Condition(s):Advanced Solid TumorsLast Updated:October 24, 2023Not yet recruiting
Condition(s):Advanced Solid TumorLast Updated:November 1, 2021Active, not recruiting
Condition(s):Advanced Solid TumorLast Updated:October 3, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:November 28, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.